Q BioMed Takes the Stage in the Expanded Access Debate at European Early and...
Q BioMed Orphan Drug VP, who started the first Expanded Access Program Database asked to Speak on Panels and run Roundtable at the Early and Managed Access Program Conference in the UK from October...
View ArticleQ BioMed Provides Important Update on QBM001 Developmental Drug Targeting a...
Company Further Develops Its Autistic Spectrum Disorder (ASD) Drug Technology and Expects Several Development Partnerships In Anticipation of Clinical Program in 2019 NEW YORK, October 9, 2018...
View ArticleQ Biomed Inc. Announces Entry Into Definitive Funding Agreement for $4,000,000
Financing Provides Necessary Capital to Reach Important Milestones NEW YORK, September 24, 2018 /PRNewswire/ — Q BioMed Inc. (OTCQB: QBIO), is pleased to announce that it has entered into a definitive...
View ArticleClik here to view.
Q Biomed Inc. Announces Dr. Rajendra Apte Joins Advisory Board
Distinguished Ophthalmology Specialist Brings Wealth of Experience NEW YORK, Sept. 17, 2018 /PRNewswire/ — Q BioMed Inc. (OTCQB: QBIO), a commercial stage biotechnology acceleration development...
View ArticleClik here to view.
Q BioMed Inc. Announces FDA Filing for Strontium Chloride Sr89 Injection USP...
Prior Approval Supplement Filing Under GDUFA Guidelines is Final Step in Approval Process NEW YORK, Aug. 20, 2018 /PRNewswire/ — Q BioMed Inc. (OTCQB: QBIO) (OtherOTC: QBIO), a commercial stage...
View ArticleQ Biomed Inc. Extends its Exclusive Option Agreement With Washington...
NEW YORK, July 25, 2018 /PRNewswire/ — Q BioMed Inc. (OTCQB: QBIO), a commercial stage biotechnology acceleration development company, is pleased to announce that it is extending its option agreement...
View ArticleQ BioMed Inc. Provides Important Update on Mannin Research Tie2 Technology...
NEW YORK, June 6, 2018 /PRNewswire/ — Q BioMed Inc. (OTCQB: QBIO), a commercial stage biotechnology acceleration development company, provides the following update on its exclusively licensed platform...
View ArticleQ BioMed Inc Places 2nd in Company Category for Autism Speaks Walk Fundraiser
Company makes effort to connect with patients and caregivers as it progress its potential treatment for an Autistic Spectrum Nonverbal Developmental Disorder NEW YORK, June 1, 2018 /PRNewswire/ — Q...
View ArticleQ Biomed Inc. to Present at the Microcap Conference Taking Place April 9-10...
NEW YORK, April 5, 2018 /PRNewswire/ — Q BioMed Inc. (OTCQB: QBIO), a commercial stage biotechnology acceleration company, announced today that Denis Corin, Chief Executive Officer, will present at...
View ArticleQ Biomed Inc. Announces FDA Filing for Approval of a New Manufacturing...
NEW YORK, March 16, 2018 /PRNewswire/ — Q BioMed Inc. (OTCQB: QBIO), a commercial stage biotechnology acceleration development company, and Bio-Nucleonics, licensor of Strontium 89 Chloride, announce...
View ArticleQ BioMed Inc. to Present at 30th Annual Roth Conference, Taking Place March...
NEW YORK, March 9, 2018 /PRNewswire/ — Q BioMed Inc. (OTCQB: QBIO), a commercial stage biotechnology acceleration company, announced today that Denis Corin, Chief Executive Officer will present at the...
View ArticleWashington University researchers evaluate biomarker for glaucoma
Q BioMed Inc., a biomedical acceleration and development company, along with researchers at Washington University in St. Louis have begun evaluating the feasibility of GDF-15, a novel biomarker for...
View ArticleQ BioMed Adds Big Pharma Executive to Board of Directors
Veteran Novartis and WuXii Global Head of Pharmaceutical Development Joins Company Board NEW YORK, February 13, 2018 /PRNewswire/ — Q BioMed Inc. (OTCQB: QBIO), a biotechnology acceleration company, is...
View ArticleQ Biomed Inc. Signs Exclusive Option Agreement With Washington University in...
Potential Companion Diagnostic Compliments MAN-01 Pipeline Glaucoma Drug NEW YORK, February 8, 2018 /PRNewswire/ — Q BioMed Inc. (OTCQB: QBIO), is pleased to announce an exclusive option agreement with...
View ArticleQ Biomed Inc. Closes $5.48 Million Public Offering
Company Expects Commercialization and Revenue from its Non-Opioid Pain Palliation Drug in Q2 2018 and Initiation of Multiple Pivotal Clinical Programs in 2018 NEW YORK, February 1, 2018 /PRNewswire/ —...
View ArticleQ BioMed Inc. Prices $5.5 Million Public Offering
Proceeds To Fund Commercialization of First Approved Drug and Pivotal Clinical Programs in 2018 NEW YORK, January 30, 2018 /PRNewswire/ — Q BioMed Inc. (OTCQB: QBIO) (“Q BioMed” or the “Company”), a...
View ArticleQ Biomed Inc. to Present at Biotech Showcase(™) 2018
NEW YORK, January 3, 2018 /PRNewswire/ — Q BioMed Inc. (OTCQB: QBIO), a biotechnology acceleration company announced today that Denis Corin, Chief Executive Officer, will present at the Biotech...
View ArticleClik here to view.
Q BioMed Provides Year End Update
Company Ends Year with an Advancing Full Pipeline and a Catalyst Rich Year Ahead NEW YORK, Dec. 21, 2017 /PRNewswire/ — Q BioMed Inc. (OTCQB: QBIO), a biotechnology acceleration company, is pleased to...
View ArticleQ BioMed Announces Full Settlement of All Convertible Debt
Company Closes Financial Year End With No Outstanding Convertible or Loan Debt NEW YORK, December 5, 2017 /PRNewswire/ — Q BioMed Inc. (OTCQB: QBIO), a biotechnology acceleration Company, announced...
View ArticleQ BioMed Adds Boston University’s Dr. Tager-Flusberg to Advisory Committee
Autism Language Expert Provides Primary Endpoint Protocol for Upcoming Clinical Trial NEW YORK, November 28, 2017 /PRNewswire/ — Q BioMed Inc. (OTCQB: QBIO), a biotechnology acceleration company,...
View Article
